<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Physiomics Plc — News on 6ix</title>
<link>https://6ix.com/company/physiomics-plc</link>
<description>Latest news and press releases for Physiomics Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 24 Apr 2026 09:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/physiomics-plc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835ea4e78dffbe2df12a2e3.webp</url>
<title>Physiomics Plc</title>
<link>https://6ix.com/company/physiomics-plc</link>
</image>
<item>
<title>Reminder to Vote Against Resolutions</title>
<link>https://6ix.com/company/physiomics-plc/news/reminder-to-vote-against-resolutions</link>
<guid isPermaLink="true">https://6ix.com/company/physiomics-plc/news/reminder-to-vote-against-resolutions</guid>
<pubDate>Fri, 24 Apr 2026 09:30:00 GMT</pubDate>
<description>Physiomics plc is urging shareholders to vote against all resolutions at the upcoming requisitioned General Meeting on April 29, 2026, as proposed by activist investor Mike Whitlow. The Board unanimously recommends this action, believing the proposed replacement of the entire Board with associates of the requisitioning shareholder would compromise the company's independence and expertise. Independent proxy advisor ISS also recommends voting against all resolutions. The Board argues the requisiti</description>
</item>
<item>
<title>Launch of Website for Requisitioned Meeting</title>
<link>https://6ix.com/company/physiomics-plc/news/launch-of-website-for-requisitioned-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/physiomics-plc/news/launch-of-website-for-requisitioned-meeting</guid>
<pubDate>Wed, 22 Apr 2026 06:00:00 GMT</pubDate>
<description>Physiomics plc has launched a dedicated website, www.pycrequisition.co.uk, to provide shareholders with transparent information regarding the upcoming Requisitioned General Meeting on April 29, 2026. The site includes details on the requisition, the Board's position and recommendations, and voting instructions, aiming to ensure shareholders can make informed decisions.
Disclaimer*</description>
</item>
<item>
<title>ISS Voting Recommendation</title>
<link>https://6ix.com/company/physiomics-plc/news/iss-voting-recommendation</link>
<guid isPermaLink="true">https://6ix.com/company/physiomics-plc/news/iss-voting-recommendation</guid>
<pubDate>Fri, 17 Apr 2026 06:00:00 GMT</pubDate>
<description>Physiomics plc announced that Institutional Shareholder Services Inc. (ISS), an independent proxy adviser, recommends shareholders vote "AGAINST" all resolutions at the upcoming Requisitioned General Meeting to remove the current Board and appoint new directors. ISS found that the requisitioners have not presented a sufficiently detailed or credible plan to support a full board replacement. This recommendation aligns with the Company's Board, which highlights that the first half of the financial</description>
</item>
<item>
<title>Requestioned GM and Investor Presentation</title>
<link>https://6ix.com/company/physiomics-plc/news/requestioned-gm-and-investor-presentation</link>
<guid isPermaLink="true">https://6ix.com/company/physiomics-plc/news/requestioned-gm-and-investor-presentation</guid>
<pubDate>Wed, 08 Apr 2026 06:00:00 GMT</pubDate>
<description>Physiomics plc is holding a Requisitioned General Meeting on April 29, 2026, where the Board recommends shareholders vote against proposed resolutions, citing concerns about the suitability and preparedness of the proposed new directors. The company highlights its recent financial performance, with total income for the first half of the current financial year being 51% higher than the previous comparable period and projecting a 27% increase for the full year ending June 2026. An investor present</description>
</item>
<item>
<title>Circular & Notice of Requisitioned GM</title>
<link>https://6ix.com/company/physiomics-plc/news/circular-and-notice-of-requisitioned-gm-1</link>
<guid isPermaLink="true">https://6ix.com/company/physiomics-plc/news/circular-and-notice-of-requisitioned-gm-1</guid>
<pubDate>Thu, 02 Apr 2026 17:27:00 GMT</pubDate>
<description>Physiomics PLC has announced the publication of a circular and notice of a requisitioned general meeting to be held on April 29, 2026, to vote on resolutions proposed by Michael Whitlow, who holds approximately 12.35% of the company's shares. The resolutions aim to replace the entire existing board with Nicholas Tulloch, Michael Whitlow, and Ian Bagnall. The Board unanimously recommends shareholders vote AGAINST these resolutions, citing concerns about the proposed directors' suitability, lack o</description>
</item>
<item>
<title>Cancellation of General Meeting</title>
<link>https://6ix.com/company/physiomics-plc/news/cancellation-of-general-meeting-1</link>
<guid isPermaLink="true">https://6ix.com/company/physiomics-plc/news/cancellation-of-general-meeting-1</guid>
<pubDate>Fri, 20 Mar 2026 07:00:00 GMT</pubDate>
<description>Physiomics Plc has cancelled its General Meeting scheduled for April 7, 2026, as the previously proposed placing to raise approximately £500,000 at 0.3 pence per share has been superseded by a revised placing and retail offer completed on March 17, 2026, at an increased price of 0.4 pence per share. The resolutions intended for the General Meeting are no longer relevant due to the change in the placing terms. Shareholders are advised that any proxy appointments submitted for the cancelled meetin</description>
</item>
<item>
<title>WRAP Retail Offer for up to £110,000.00</title>
<link>https://6ix.com/company/physiomics-plc/news/wrap-retail-offer-for-up-to-pound11000000</link>
<guid isPermaLink="true">https://6ix.com/company/physiomics-plc/news/wrap-retail-offer-for-up-to-pound11000000</guid>
<pubDate>Tue, 17 Mar 2026 07:01:00 GMT</pubDate>
<description>Physiomics plc is undertaking a WRAP Retail Offer to raise up to £110,000 by issuing new ordinary shares at £0.004 per share, with up to 27,500,000 shares available. This offer, which is conditional on the completion of a separate placing to raise £490,000, is open to existing UK retail shareholders and is expected to close on March 18, 2026, with admission anticipated around March 20, 2026. The proceeds from both the retail offer and the placing will be used for the same purposes, and the new s</description>
</item>
<item>
<title>Completion of Placing and WRAP Retail Offer Launch</title>
<link>https://6ix.com/company/physiomics-plc/news/completion-of-placing-and-wrap-retail-offer-launch-1</link>
<guid isPermaLink="true">https://6ix.com/company/physiomics-plc/news/completion-of-placing-and-wrap-retail-offer-launch-1</guid>
<pubDate>Tue, 17 Mar 2026 07:00:00 GMT</pubDate>
<description>Physiomics plc has completed a revised placing, raising £490,000 gross through the issuance of 122,500,000 new ordinary shares at £0.004 per share, a discount to the previous day's closing price. The company is also launching a retail offer to raise up to an additional £110,000 at the same price. These funds will support business development, consulting services, personalised medicine tool development, and strategic growth exploration. This revised fundraising replaces a previously announced pla</description>
</item>
<item>
<title>General Meeting Request</title>
<link>https://6ix.com/company/physiomics-plc/news/general-meeting-request</link>
<guid isPermaLink="true">https://6ix.com/company/physiomics-plc/news/general-meeting-request</guid>
<pubDate>Mon, 16 Mar 2026 07:00:00 GMT</pubDate>
<description>Physiomics plc announced on March 16, 2026, that it received a request from shareholder Michael Whitlow, who holds approximately 13.68% of the company's shares, to convene a general meeting. The request proposes resolutions to appoint Nicholas Tulloch, Michael Whitlow, Ian Bagnall, and Martin Gouldstone as directors and to remove the current directors, Dr. Jim Millen, Shalabh Kumar, Dr. Tim Corn, and Dr. Peter Sargent. The Board is seeking legal advice on the request's compliance and stated that</description>
</item>
<item>
<title>WRAP Retail Offer for up to £49,999.98</title>
<link>https://6ix.com/company/physiomics-plc/news/wrap-retail-offer-for-up-to-pound4999998</link>
<guid isPermaLink="true">https://6ix.com/company/physiomics-plc/news/wrap-retail-offer-for-up-to-pound4999998</guid>
<pubDate>Tue, 10 Mar 2026 07:01:00 GMT</pubDate>
<description>Physiomics plc is undertaking a WRAP Retail Offer to raise up to £49,999.98 through the issuance of up to 16,666,660 new ordinary shares at £0.003 per share. This offer is concurrent with a larger placing aiming to raise approximately £499,999.86 at the same price per share, representing a discount of about 33.33% to the previous day's closing price. The proceeds from both the retail offer and the placing will be used for the same purposes, and the retail offer's completion is conditional upon t</description>
</item>
<item>
<title>Completion of Placing, Retail Offer & Notice of GM</title>
<link>https://6ix.com/company/physiomics-plc/news/completion-of-placing-retail-offer-and-notice-of-gm</link>
<guid isPermaLink="true">https://6ix.com/company/physiomics-plc/news/completion-of-placing-retail-offer-and-notice-of-gm</guid>
<pubDate>Tue, 10 Mar 2026 07:00:00 GMT</pubDate>
<description>Physiomics plc has completed a placing to raise £449,999.88 gross through the issue of 149,999,960 new ordinary shares at £0.003 per share, representing a 33.33% discount to the previous day's closing price. The company will also launch a retail offer to raise up to an additional £49,999.98. These funds will be used for business development, marketing, expanding internal capabilities, developing its Personalised Dosing Software, and exploring strategic growth options. This follows a period of si</description>
</item>
<item>
<title>Holding(s) in Company</title>
<link>https://6ix.com/company/physiomics-plc/news/holdings-in-company-433</link>
<guid isPermaLink="true">https://6ix.com/company/physiomics-plc/news/holdings-in-company-433</guid>
<pubDate>Mon, 02 Feb 2026 11:40:00 GMT</pubDate>
<description>Mike Whitlow has acquired a significant stake in Physiomics PLC, now holding 7.42063% of the company's voting rights, which equates to 2,250,000 shares. This notification, dated January 30, 2026, indicates an acquisition of voting rights, with no financial instruments involved. Mr. Whitlow is not controlled by any other entity and does not control any other undertakings holding an interest in Physiomics PLC.
Disclaimer*</description>
</item>
<item>
<title>Physiomics Awarded New Contract by Numab</title>
<link>https://6ix.com/company/physiomics-plc/news/physiomics-awarded-new-contract-by-numab</link>
<guid isPermaLink="true">https://6ix.com/company/physiomics-plc/news/physiomics-awarded-new-contract-by-numab</guid>
<pubDate>Wed, 28 Jan 2026 07:00:00 GMT</pubDate>
<description>Physiomics plc has secured a new contract with Numab Therapeutics AG to develop a pharmacokinetic-pharmacodynamic (PK/PD) model for a key asset in Numab's Immunology and Inflammation pipeline. This collaboration aims to accelerate therapeutic development by informing the Target Candidate Profile and supporting early-stage, data-driven decision-making, with completion anticipated in the second quarter of 2026.
Disclaimer*</description>
</item>
<item>
<title>Options Award</title>
<link>https://6ix.com/company/physiomics-plc/news/options-award-1</link>
<guid isPermaLink="true">https://6ix.com/company/physiomics-plc/news/options-award-1</guid>
<pubDate>Tue, 23 Dec 2025 07:00:00 GMT</pubDate>
<description>Physiomics plc has awarded share options to Jesse Thissen, Head of Biometrics, to incentivize shareholder value creation. This includes 1,516,044 options at a 41% premium (0.41 pence), vesting one year after employment, and another 3,032,088 options at 172% (0.79 pence) and 345% (1.29 pence) premiums, vesting over three years from July 2026. These awards are intended to recognize Mr. Thissen's integral role in launching the new Biometrics service line, which has already secured three contracts s</description>
</item>
<item>
<title>Physiomics Awarded Follow On Contract by UK Client</title>
<link>https://6ix.com/company/physiomics-plc/news/physiomics-awarded-follow-on-contract-by-uk-client</link>
<guid isPermaLink="true">https://6ix.com/company/physiomics-plc/news/physiomics-awarded-follow-on-contract-by-uk-client</guid>
<pubDate>Mon, 15 Dec 2025 07:00:00 GMT</pubDate>
<description>Physiomics plc has secured a follow-on contract with an existing UK client, valued between £116,000 and £169,000, to support a Phase 2 clinical study for a rheumatoid arthritis therapeutic. This new project builds upon previous work and is expected to commence in 2027, running for approximately six months. The contract highlights the client's continued commitment and provides Physiomics with an opportunity to expand its project pipeline for the upcoming financial year.
Disclaimer</description>
</item>
<item>
<title>Physiomics Awarded New Contract by GARDP</title>
<link>https://6ix.com/company/physiomics-plc/news/physiomics-awarded-new-contract-by-gardp</link>
<guid isPermaLink="true">https://6ix.com/company/physiomics-plc/news/physiomics-awarded-new-contract-by-gardp</guid>
<pubDate>Wed, 10 Dec 2025 07:00:00 GMT</pubDate>
<description>Physiomics plc has secured a new contract with GARDP Foundation to provide expert consultancy support for optimizing the design of an efficacy trial within their Serious Bacterial Infections programme, with work commencing in January 2026 and expected to conclude within three months. This marks the company's second major client in its Biometrics department, which has surpassed initial projections since its launch, representing a significant milestone and a promising contribution to Physiomics' g</description>
</item>
<item>
<title>Physiomics Awarded Two New Contracts</title>
<link>https://6ix.com/company/physiomics-plc/news/physiomics-awarded-two-new-contracts</link>
<guid isPermaLink="true">https://6ix.com/company/physiomics-plc/news/physiomics-awarded-two-new-contracts</guid>
<pubDate>Thu, 04 Dec 2025 07:00:00 GMT</pubDate>
<description>Physiomics plc has secured two new modelling and simulation contracts totaling £29,750, with one contract valued at £13,600 extending an existing relationship with a UK biotech firm using the Virtual Tumour Platform for oncology drug dosing, and another new contract worth £16,150 with a UK biotech client focused on renal disease therapies, which may lead to further projects.
Disclaimer*</description>
</item>
<item>
<title>Board Changes</title>
<link>https://6ix.com/company/physiomics-plc/news/board-changes-127</link>
<guid isPermaLink="true">https://6ix.com/company/physiomics-plc/news/board-changes-127</guid>
<pubDate>Wed, 03 Dec 2025 07:00:00 GMT</pubDate>
<description>Physiomics plc announced that Executive Director and CEO Peter Sargent will step down on May 29, 2026, with Non-Executive Chairman Dr. Jim Millen prepared to resume the Executive Chairman role to ensure business continuity. The company expects total revenues to be in line with market expectations and will release its interim results for the half-year ending December 31, 2025, in early March 2026. Dr. Sargent's departure follows a period of significant progress, including notable revenue increase</description>
</item>
<item>
<title>Result of AGM</title>
<link>https://6ix.com/company/physiomics-plc/news/result-of-agm-380</link>
<guid isPermaLink="true">https://6ix.com/company/physiomics-plc/news/result-of-agm-380</guid>
<pubDate>Tue, 18 Nov 2025 15:43:00 GMT</pubDate>
<description>Physiomics plc announced that all resolutions presented at its annual general meeting were passed, including the approval of accounts with 98.8% of votes for, the re-election of directors Dr. Jim Millen (94.6% for) and Dr. Tim Corn (94.5% for), and the appointment of the auditor (98.6% for). Shareholders also approved the authority to allot shares with 85.9% of votes for and the disapplication of pre-emption rights with 81.9% of votes for, indicating strong shareholder support for the company's </description>
</item>
<item>
<title>Notice of AGM</title>
<link>https://6ix.com/company/physiomics-plc/news/notice-of-agm-188</link>
<guid isPermaLink="true">https://6ix.com/company/physiomics-plc/news/notice-of-agm-188</guid>
<pubDate>Fri, 17 Oct 2025 06:00:00 GMT</pubDate>
<description>Physiomics PLC announced that its Annual General Meeting (AGM) will be held on November 18, 2025, at 10:30 a.m. The meeting will take place at Bee House, 140 Eastern Avenue, Milton Park, Oxfordshire, OX14 4SB. Shareholders will receive either printed copies of the Notice of AGM and accompanying materials or a notification that these documents are available on the company's website, based on their registrar preferences. The Notice of AGM, detailing the resolutions to be proposed, along with the C</description>
</item>
</channel>
</rss>